Inj, tocilizumab-bavi, 1mg
Products billed under this code include Tofidence.
Payment limit per 1 MG, by effective quarter, 3Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under Q0234
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Tofidence | Biogen MA Inc | 64406-0022-01 | 200 | $1,265.40 |
| Tofidence | Biogen MA Inc | 64406-0023-01 | 400 | $2,530.80 |
| Tofidence | Biogen MA Inc | 64406-0024-01 | 80 | $506.16 |
| Tofidence | Organon LLC | 78206-0200-01 | 80 | $506.16 |
| Tofidence | Organon LLC | 78206-0201-01 | 200 | $1,265.40 |
| Tofidence | Organon LLC | 78206-0202-01 | 400 | $2,530.80 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $6.327 | $0.00 | 1 MG | Inj, tocilizumab-bavi, 1mg | v1, posted September 17, 2026 |
| 3Q26 | $6.327 | – | 1 MG | Inj, tocilizumab-bavi, 1mg | v1, posted September 15, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026